On July 9, 2025, Evercore ISI Group's analyst Ross Muken reaffirmed the 'Outperform' rating for Charles River (CRL, Financial). The investment firm also upgraded its price target for CRL, raising it from $170.00 to $180.00.
The new price target of $180.00 represents a 5.88% increase from the previous target of $170.00. The decision to maintain the 'Outperform' rating alongside the raised price target indicates positive sentiment towards Charles River's future performance.
Charles River (CRL, Financial) is listed on the New York Stock Exchange and operates in USD. With this latest adjustment, stakeholders and potential investors may perceive the company's outlook as favorable.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 14 analysts, the average target price for Charles River Laboratories International Inc (CRL, Financial) is $153.89 with a high estimate of $182.00 and a low estimate of $70.00. The average target implies an downside of 2.84% from the current price of $158.39. More detailed estimate data can be found on the Charles River Laboratories International Inc (CRL) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Charles River Laboratories International Inc's (CRL, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Charles River Laboratories International Inc (CRL, Financial) in one year is $203.26, suggesting a upside of 28.33% from the current price of $158.39. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Charles River Laboratories International Inc (CRL) Summary page.
